Efficacy of donepezil in early-stage Alzheimer disease: A randomized placebo-controlled trial

Archives of Neurology

Volumn 61, Issue 12, 2004, Pages 1852-1856

  Seltzer, Ben ^a   Zolnouni, Parvaneh ^b   Nunez, Margarita ^c   Goldman, Robert ^d   Kumar, Dinesh ^e   Ieni, John ^e   Richardson, Sharon ^e  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CALIFORNIA CLINICAL TRIALS   (United States)

^c ICSL Clinical Studies   (United States)

^d PFIZER INC   (United States)

^e EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASTHENIA; BRAIN HEMORRHAGE; CAROTID ARTERY OBSTRUCTION; CLINICAL TRIAL; COGNITION; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DREAMING; DRUG EFFICACY; DRUG SAFETY; FALLING; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECALL; SLEEP DISORDER; SYNCOPE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INDANS; MALE; MIDDLE AGED; PIPERIDINES;

EID: 10044228581     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.12.1852     Document Type: Article

References (26)

1. Rogers SL, Doody RS, Mohs RC, Friedhoff LT; Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Meet. 1998;158:1021-1031.
2. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT; Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-145.
3. Knopman D, Donohue JA, Gutterman EM. Patterns of care in the early stages of Alzheimer's disease: impediments to timely diagnosis. J Am Geriatr Soc. 2000;48:300-304.
4. Larrabee GJ, Crook TI. A computerized battery for assessment of everyday memory. In: West R, Sinnott J, eds. Every Day Memory and Aging. New York: Springer-Verlag NY Inc; 1992:54-65.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Text Revision. Washington, DC: American Psychiatric Press; 2000.
6. McKhann G, Drachmen D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
7. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980;7:486-488.
8. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
9. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
10. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Discret. 1997;11(suppl 2):S13-S21.
11. Crook TH, Youngjohn J, Larrabee G, Salama M. Aging and everyday memory: a cross cultural study. Neuropsychology. 1992;6:123-136.
12. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1992;4:134-139.
13. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer's disease. Arch Neuro. 2001;58:397-405.
14. Galasko D. An integrated approach to the management of Alzheimer's disease: assessing cognition, function and behaviour [abstract]. Eur J Neurol. 1998;5(suppl 4):S9-S17.
15. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10:237-244.
16. Almkvist O, Basun H, Backman L, et al. Mild cognitive impairment: an early stage of Alzheimer's disease? J Neural Transm Suppl. 1998;54:21-29.
17. Gilley DW, Wilson RS, Bennett DA, Bernard BA, Fox JH. Predictors of behavioral disturbance in Alzheimer's disease. J Gerontol. 1991;46:P362-P371.
18. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD; Donepezil Study Group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol. 2001;58:427-433.
19. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [published erratum appears in Neurology. 2001;57:1942]. Neurology. 2001;57:481-488.
20. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [published erratum appears in Neurology. 2001;57:1942]. Neurology. 2001;57:481-488.
21. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;72:310-314.
22. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51:937-944.
23. Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry. 2003;160:2003-2011.
24. 3H]MK-801 binding in rat cerebral cortex. Neurosci Lett. 1999;272:21-24.
25. Takada Y, Yonezawa A, Kume T, et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther. 2003;306:772-777.
26. Akasofu S, Kosasa T, Kimura M, Kubota A. Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur J Pharmacol. 2003;472:57-63.